<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35500358</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-8511</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>31</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</Title>
          <ISOAbbreviation>J Stroke Cerebrovasc Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lack of Association between Seropositivity of Vasculopathy-Related Viruses and Moyamoya Disease.</ArticleTitle>
        <Pagination>
          <StartPage>106509</StartPage>
          <MedlinePgn>106509</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jstrokecerebrovasdis.2022.106509</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1052-3057(22)00203-8</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Although the association between genetic factors, such as RNF213 mutations, and moyamoya disease (MMD) has been well investigated, environmental factors are largely undetermined. Thus, we aimed to examine whether viral infection increases the risk of MMD.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">To eliminate the effect of presence or absence of the RNF213 p.R4810K mutation, the entire study population was positive for this mutation. We collected whole blood from 111 patients with MMD (45 familial and 66 sporadic cases) and 67 healthy volunteers, and we measured the immunoglobulin G titer of 11 viruses (cytomegalovirus, varicella-zoster virus, measles virus, rubella virus, herpes simplex virus, mumps virus, Epstein-Barr virus, human parvovirus B19, human herpesvirus 6 [HHV6], human herpesvirus 8, and John Cunningham virus) that were presumed to be associated with vasculopathy using the enzyme-linked immunosorbent assay. Positivity for past viral infection was determined by cut-off values obtained from previous reports and the manufacturer's instructions, and the positive rate was compared between cases and age- and sex-matched controls. We performed familial case-specific and sporadic case-specific analyses, as well as a case-control analysis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no significant difference in the positive rate between the case group and the control group in any of the analyses. A significant difference was only observed in the combined case-control analysis for HHV6 (p = 0.046), but the viral antibody-positive rate in control individuals was higher than in MMD cases.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our cross-sectional study suggest that the investigated 11 viruses including HHV6 are unlikely to have an impact on MMD development.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nakamura</LastName>
            <ForeName>Yasuhisa</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health and Environmental Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mineharu</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan; Department of Artificial Intelligence in Healthcare and Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. Electronic address: mineharu@kuhp.kyoto-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kamata</LastName>
            <ForeName>Takahiko</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Funaki</LastName>
            <ForeName>Takeshi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miyamoto</LastName>
            <ForeName>Susumu</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koizumi</LastName>
            <ForeName>Akio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Social Health Medicine Welfare Laboratory, Public Interest Incorporated Association Kyoto Hokenkai, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harada</LastName>
            <ForeName>Kouji H</ForeName>
            <Initials>KH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health and Environmental Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. Electronic address: kharada-hes@umin.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Stroke Cerebrovasc Dis</MedlineTA>
        <NlmUniqueID>9111633</NlmUniqueID>
        <ISSNLinking>1052-3057</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.3.2.27</RegistryNumber>
          <NameOfSubstance UI="C557998">RNF213 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.2.27</RegistryNumber>
          <NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536991">Moyamoya disease 1</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000251" MajorTopicYN="N">Adenosine Triphosphatases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009072" MajorTopicYN="Y">Moyamoya Disease</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">IgG antibody, RNF213, Familial</Keyword>
        <Keyword MajorTopicYN="N">Moyamoya disease</Keyword>
        <Keyword MajorTopicYN="N">Titer</Keyword>
        <Keyword MajorTopicYN="N">Viral infection</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of Interest Statement Akio Koizumi holds a patent for RNF213 (JPWO2011049207A1), “Moyamoya disease-related genes and their use.” The other authors report no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>18</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35500358</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2022.106509</ArticleId>
        <ArticleId IdType="pii">S1052-3057(22)00203-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35500358</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-8511</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>31</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association</Title>
          <ISOAbbreviation>J Stroke Cerebrovasc Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Lack of Association between Seropositivity of Vasculopathy-Related Viruses and Moyamoya Disease.</ArticleTitle>
        <Pagination>
          <StartPage>106509</StartPage>
          <MedlinePgn>106509</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jstrokecerebrovasdis.2022.106509</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1052-3057(22)00203-8</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Although the association between genetic factors, such as RNF213 mutations, and moyamoya disease (MMD) has been well investigated, environmental factors are largely undetermined. Thus, we aimed to examine whether viral infection increases the risk of MMD.</AbstractText>
          <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">To eliminate the effect of presence or absence of the RNF213 p.R4810K mutation, the entire study population was positive for this mutation. We collected whole blood from 111 patients with MMD (45 familial and 66 sporadic cases) and 67 healthy volunteers, and we measured the immunoglobulin G titer of 11 viruses (cytomegalovirus, varicella-zoster virus, measles virus, rubella virus, herpes simplex virus, mumps virus, Epstein-Barr virus, human parvovirus B19, human herpesvirus 6 [HHV6], human herpesvirus 8, and John Cunningham virus) that were presumed to be associated with vasculopathy using the enzyme-linked immunosorbent assay. Positivity for past viral infection was determined by cut-off values obtained from previous reports and the manufacturer's instructions, and the positive rate was compared between cases and age- and sex-matched controls. We performed familial case-specific and sporadic case-specific analyses, as well as a case-control analysis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no significant difference in the positive rate between the case group and the control group in any of the analyses. A significant difference was only observed in the combined case-control analysis for HHV6 (p = 0.046), but the viral antibody-positive rate in control individuals was higher than in MMD cases.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our cross-sectional study suggest that the investigated 11 viruses including HHV6 are unlikely to have an impact on MMD development.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nakamura</LastName>
            <ForeName>Yasuhisa</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health and Environmental Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mineharu</LastName>
            <ForeName>Yohei</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan; Department of Artificial Intelligence in Healthcare and Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. Electronic address: mineharu@kuhp.kyoto-u.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kamata</LastName>
            <ForeName>Takahiko</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Funaki</LastName>
            <ForeName>Takeshi</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miyamoto</LastName>
            <ForeName>Susumu</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Koizumi</LastName>
            <ForeName>Akio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Social Health Medicine Welfare Laboratory, Public Interest Incorporated Association Kyoto Hokenkai, Kyoto, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Harada</LastName>
            <ForeName>Kouji H</ForeName>
            <Initials>KH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Health and Environmental Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. Electronic address: kharada-hes@umin.ac.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Stroke Cerebrovasc Dis</MedlineTA>
        <NlmUniqueID>9111633</NlmUniqueID>
        <ISSNLinking>1052-3057</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.3.2.27</RegistryNumber>
          <NameOfSubstance UI="C557998">RNF213 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.3.2.27</RegistryNumber>
          <NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.1.-</RegistryNumber>
          <NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536991">Moyamoya disease 1</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000251" MajorTopicYN="N">Adenosine Triphosphatases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009072" MajorTopicYN="Y">Moyamoya Disease</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014777" MajorTopicYN="Y">Virus Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">IgG antibody, RNF213, Familial</Keyword>
        <Keyword MajorTopicYN="N">Moyamoya disease</Keyword>
        <Keyword MajorTopicYN="N">Titer</Keyword>
        <Keyword MajorTopicYN="N">Viral infection</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of Interest Statement Akio Koizumi holds a patent for RNF213 (JPWO2011049207A1), “Moyamoya disease-related genes and their use.” The other authors report no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>3</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>18</Hour>
          <Minute>17</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35500358</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jstrokecerebrovasdis.2022.106509</ArticleId>
        <ArticleId IdType="pii">S1052-3057(22)00203-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
